Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL13300979 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14601228 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL15866631 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL18613184 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14445014 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL13279561 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14077137 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22450052 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22022258 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL13529124 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021083310-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | 深圳艾欣达伟医药科技有限公司 | 2021-05-06 | — | — | WO | claimed |
| CN-100490850-C | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN NINGBO YINGNUO PHARMACE (CN) | 2009-05-27 | — | — | CN | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-1236758-C | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2006-01-18 | — | — | CN | claimed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | claimed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-102713618-B | Protein Kinase Complexes and Inhibitors | CELGENE AVILOMICS RES INC | 2015-07-15 | — | — | CN | disclosed |
| EP-2776387-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | Emory University (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013078392-A1 | METHODS AND COMPOSITIONS INVOLVING INDUCED SENESCENT CELLS FOR CANCER TREATMENT | THE UNIVERSITY OF CHICAGO (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130023897-A1 | Devices and Methods for Endovascular Therapies | CARDIOPROLIFIC INC. | 2013-01-24 | — | — | US | disclosed |
| WO-2005032492-A2 | SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004055175-A1 | METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF | TJOETTA ENOK (NO) | 2004-07-01 | — | — | WO | disclosed |
| EP-1390075-A2 | CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY | The University of Chicago (US) | 2004-02-25 | — | — | EP | disclosed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | disclosed |
| WO-2002080849-A2 | CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY | UNIVERSITY OF CHICAGO (US) | 2002-10-17 | — | — | WO | disclosed |
| US-5859013-A | ADMINISTERING TO TREAT MULTIDRUG RESISTANT CANCERS | HITACHI CHEMICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5733911-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | HITACHI CHEMICAL CO., LTD. (JP) | 1998-03-31 | — | — | US | disclosed |